Sign in
Taking people in United StatesPhase 2

Semaglutide Trial for Weight and Heart Risk in Young Adults With Type 1 Diabetes

Tests semaglutide against placebo in young adults with type 1 diabetes and obesity.

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Registry title
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
Status
Recruiting
Phase
Phase 2
People taking part
54 people, planned
Started
16 Jul 2024
Expected to end
30 Jun 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Semaglutide Pen Injector
  • Placebo
Record updated
4 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for young adults aged 18-30 with type 1 diabetes and obesity or overweight. It tests semaglutide (a GLP-1 medicine) against placebo and looks at heart and metabolic risk markers.

Age
18 to 30 years
Sex
All sexes
Disease stage
Type 1 diabetes diagnosed at least 12 months ago. BMI of 30 kg/m2 or more, or 27 kg/m2 or more with a weight-related health problem. HbA1c of 10% (86 mmol/mol) or less.
Earlier treatment
Stable insulin dose and stable BMI in the past 90 days. Real-time continuous glucose monitoring in use. No other diabetes add-on medicines or anti-obesity medicines, including any GLP-1 agonist, now or in the past 6 months.
Biomarker or test result
HbA1c of 10% (86 mmol/mol) or less at screening and within the past 90 days. Creatinine under 1.0 mg, triglycerides under 400 mg/dl (4.5 mmol/L), ALT under 3.5 times the upper normal limit.

Main reasons for not taking part

  • Pregnant, breast-feeding, planning pregnancy, or not using adequate contraception
  • History of pancreatitis, kidney problems, or liver disease other than non-alcoholic hepatic steatosis
  • Personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia Type 2
  • Allergy to semaglutide or related products, or corn allergy
  • Diabetic ketoacidosis in the past 6 months, or severe low blood sugar needing hospital care in the past 3 months

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Age 18-30 years with T1D whose BMI meets FDA approval criteria for anti-obesity pharmacotherapy (BMI ≥30 kg/m2 alone or BMI ≥27 kg/m2 with a weight-related comorbidity)
  • Clinical diagnosis of T1D
  • Diabetes duration diagnosed ≥ 12 months ago
  • HbA1c ≤10% at screening and within the past 90 days
  • Stable reported insulin dosing in the past 90 days (within 15%)
  • Stable reported BMI in the past 90 days (within 5%)
  • Ability to provide written informed consent before any trial-related activities
  • Use of real-time continuous glucose monitoring and planned continued use
  • Females and males of childbearing potential willing to use highly effective methods of contraception for at least 1 month prior to randomization and agreement to use such a method during study participation and for 2 months after the last dose of study medication administration: Combined estrogen-progestogen contraception including: oral, intravaginal, transdermal (patch), Progestogen-only contraception: oral, injectable or implantable, Placement of an intrauterine device or intrauterine system, Bilateral tubal occlusion (fallopian tubes are blocked), Male partner sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate), or Complete sexual abstinence from male-female sex)
  • Stated willingness to comply with all study procedures, medication regimen, and availability for the duration of the study
  • Participants cannot be randomized if any laboratory safety parameter at screening is outside the below extended laboratory ranges. For randomization, participants should have; Creatinine <1.0mg; Triglycerides (<400 mg/dl); ALT <3.5 times the upper normal limit (UNL)

Who cannot take part

  • Use of lipid lowering medications other than statins and omega-3 products
  • Previous randomization in this trial. Participants who enrolled but did not randomize can be re-screened. Potential reasons for enrolment without randomization include scheduling conflicts for the baseline studies, or for females, not yet meeting the highly effective methods of contraception criteria
  • Treatment with another investigational drug or other intervention within the past 1 month
  • Use of adjunctive diabetes therapies or anti-obesity medications (including any GLP-1 agonist) currently or within the past 6 months
  • Current psychiatric conditions impacting weight, including known eating disorders
  • Contraindications to study medications, including:; Personal history of pancreatitis, renal impairment, or known liver disease other than non-alcoholic hepatic steatosis; Personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia Type 2; Known or suspected allergy to semaglutide, excipients, or related products
  • Subjects with a PHQ-9 score >15 or those found to have a lifetime history of suicide attempts, or suicidal ideation within the past 3 months on the C-SSRS
  • Corn allergy
  • Anemia or known hematologic condition impacting HbA1c reading, or another medical condition that precludes participation
  • Insulin dosing <0.5 units/kg/day
  • Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures
  • Diabetic ketoacidosis in the past 6 months
  • Not meeting MRI safety criteria or claustrophobia preventing participation in the MRI
  • Subjects with severe hypoglycemia requiring hospitalization in the past 3 months
  • Clinically significant gastroparesis

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 30 years old?

Where in United States

  • Yale Pediatric Diabetes Center, Adult and Children's ProgamNew Haven, United StatesContact: Rehema MtawaliTaking people

About the trial

What the trial wants to find out

More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and obesity.

The 2 groups in the trial

  • SemaglutideTreatment being tested

    Participants in this arm will receive semaglutide (escalated to 2.4mg or max tolerated dose) weekly for 12 months. Then a 4 week wean period plus 2 weeks as needed insulin titration.

    Treatment: Semaglutide Pen Injector

  • PlaceboPlacebo, for comparison

    Participants in this arm will receive a matched placebo weekly for 12 months. Then a 4 week wean period plus 2 weeks as needed insulin titration.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Obesity Complicating Type 1 Diabetes in Young Adults: Physiology and Impact of GLP-1 Analogue Anti-obesity Treatment on Cardiometabolic Risk Factors
Plain-language title
Semaglutide Trial for Weight and Heart Risk in Young Adults With Type 1 DiabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06411210, who can take part
Record updated
4 August 2026